

**SYNTHESIS OF CONJUGATES OF 5'-O-CARBOXYMETHYL-  
-5-HALOGENO-2'-DEOXYURIDINES  
AND 5'-O-CARBOXYMETHYL-5-HALOGENOURIDINES  
WITH PROTEINS\***

Helmut PISCHEL<sup>a</sup>, Antonín HOLÝ<sup>b</sup> and Günther WAGNER<sup>a</sup>

<sup>a</sup> *Sektion Biowissenschaften-Pharmazie, Karl-Marx-Universität, Leipzig, G.D.R. and*

<sup>b</sup> *Institute of Organic Chemistry and Biochemistry,  
Czechoslovak Academy of Sciences, 166 10 Prague, Czechoslovakia*

Received June 26th, 1979

5'-O-Carboxymethyl-2'-deoxyuridine (*Ia*), its 5-fluoro, 5-bromo and 5-iodo derivatives *Ib—Id*, and 5'-O-carboxymethyluridine (*IIa*) and its 5-halogeno derivatives *IIb—IIId*, on reaction with isobutyl chloroformate and tri-*n*-butylamine afforded mixed anhydrides *IIIa—IIIId* and *IVa—IVd*. Condensation of *III* and *IV* with human serum albumin or bovine gamma-globulin at pH 8.0 gave conjugates *Va—Vd* to *VIIIa—VIIIId*, the yield of the covalently bound haptene being 28 to 43%.

Some 5-halogenouracils and their N<sub>1</sub>-substituted derivatives — including ribo- and 2'-deoxyribonucleosides — exhibit cytostatic, virostatic and immunosuppressive properties<sup>1,2</sup>. We tried therefore to synthesize protein conjugates, containing such compounds in a covalently bonded form with the aim to obtain potent, specifically acting, immunosuppressants<sup>3,4</sup>. Towards this end we worked out syntheses of N<sub>1</sub>-carboxymethyl-5-halogenouracils<sup>2</sup>, 5'-O-carboxymethyl-5-halogeno-2'-deoxyuridines (*I*) and 5'-O-carboxymethyl-5-halogenouridines (*II*) (ref.<sup>2,5</sup>), which, *via* their activated 4-nitrophenyl esters, reacted with proteins to give the corresponding conjugates<sup>6</sup>. Although this method gives satisfactory yields and a high degree of the haptene bonding, it requires isolation of active esters and purification of the products by gel filtration, since *p*-nitrophenol and contingent other side products formed in the reaction, cannot be removed by dialysis. Of other methods of bonding to proteins, there was described condensation of 5-fluoro-2'-deoxyuridine with albumin using a soluble carbodiimide<sup>7</sup>. This method, however, is accompanied by intramolecular reactions of the protein, leading to cross-linking and lower solubility of the conjugates<sup>8</sup>.

The mentioned drawbacks could be removed by an alternative procedure, based on use of mixed anhydrides (ref.<sup>9-11</sup>). The reaction conditions used in this method exclude also side reactions of the 5-halogenouracil nucleus with the reagent, *i.e.*

\* Part XXVI in the series Immunosuppressant Antigene Conjugates; Part XXV: This Journal 44, 3023 (1979).

TABLE I  
UV-Spectra of Compounds I ( $\epsilon$  values in parentheses, wavelength in nm).


Compound	$\lambda$	Water pH 7	Ammonium carbonate buffer, pH 8.7	0.01M-NaOH pH 12
<i>Ia</i>	Max	260 (10 000)	260 (8 700)	260 (7 500)
	Min	231	234	243
<i>Ib</i>	Max	269 (8 900)	267 (6 800)	267 (6 800)
	Min	234	248	248
<i>Ic</i>	Max	279 (9 240)	276 (6 600)	276 (6 600)
	Min	242	252	252
<i>Id</i>	Max	288 (7 000)	282 (5 380)	280 (5 300)
	Min	247	253	253

TABLE II  
Properties of the Conjugates V—VIII

Product	Excess of haptene <sup>a</sup>	Yield %	Haptene content, % <sup>b</sup>	Substitution degree <sup>c</sup>
<i>Va</i>	25	43.2	3.43	10.8
<i>Va</i>	50	38.0	5.89	19.0
<i>Vc</i>	50	32.1	6.67	16.1
<i>Vd</i>	50	35.2	8.61	17.6
<i>Vla</i>	50	29.8	4.98	14.9
<i>Vlb</i>	50	42.0	7.33	21.0
<i>Vlc</i>	50	30.9	6.86	15.5
<i>Vld</i>	50	32.1	7.62	16.1
<i>Vlla</i>	25	41.9	2.89	21.0
<i>Vllb</i>	50	36.2	4.89	36.2
<i>Vllc</i>	50	36.9	6.60	36.9
<i>Vlld</i>	50	32.8	7.03	32.8
<i>Vllla</i>	50	31.0	4.48	31.0
<i>Vlllb</i>	50	39.6	6.14	39.6
<i>Vlllc</i>	25	34.0	3.62	17.0
<i>Vllld</i>	50	28.1	5.84	28.1

<sup>a</sup> The amount of III or IV ( $\mu$ mol) used in the reaction with 1  $\mu$ mol of human serum albumin or with 0.5  $\mu$ mol of bovine gamma-globulin; <sup>b</sup> calculated for the residue of I or II; <sup>c</sup> mol of the haptene, bound to 1 mol of protein.

ester of chloroformic acid. The reaction was performed with *in situ* prepared tri-*n*-butylammonium salts of compounds *I* and *II*, which were condensed with an equimolar amount of isobutyl chloroformate in dioxane at 10°C. The obtained anhydrides *III* and *IV* were then treated directly with human serum albumin or bovine gamma-globulin in a phosphate buffer, pH 8.0. It is likely, that the  $\omega$ -amino groups of lysine moieties are bonded by stable amide bonds. The formed conjugates *V*–*VIII* were freed of compounds *I*–*II* and other side products by gel filtration.



In formulacé *I*–*VIII*,  $a R^2 = \text{H}$ ,  $b R^2 = \text{F}$ ,  $c R^2 = \text{Br}$ ,  $d R^2 = \text{I}$ ; HSA human serum albumine residue, BGG bovine  $\gamma$ -globuline residue.

The content of the covalently bound haptene and the reaction yield were determined either directly, *i.e.* by measuring the difference between the extinction coefficient of the conjugate and that of protein solution of the same concentration, or indirectly by determination of the amount of unreacted compounds *I* or *II* in the low-molecular weight fraction<sup>12</sup>. In the calculations we used the molar extinction coefficients, given in Table I. Both methods gave practically identical results which are listed in Table II. The yields ranged from 28% to 43% and the conjugates contained 15–40% (molar) of the haptene. The absorption maximum of the conjugate *Va* shifted hypsochromically with greater extent of substitution; this effect was less expressive in the case of *Vb*. All the prepared conjugates were homogeneous according to agarose gel electrophoresis and travelled to anode.

## EXPERIMENTAL

The solutions were evaporated at 40°C. Human serum albumin was purchased from Forschungsinstitut für Impfstoffe, Dessau (G. D. R.), bovine gamma-globulin from Ferak (West Berlin). Preparative gel chromatography was carried out on Sephadex G-50 coarse (Pharmacia, Sweden),

on a  $100 \times 2$  cm column, in an ammonium carbonate buffer, pH 8.7 (10 g of ammonium carbonate in 5 l of water, pH adjusted with ammonia), elution rate 1.2 ml/min, 3 ml fractions. The course of elution was followed by a Uvicord (LKB, Sweden) instrument. UV spectra were measured on a Specord UV-VIS (Zeiss, Jena, G.D.R.) spectrometer, quantitative analyses were performed on a Spectromom 203 (Hungarian Optical Works, Budapest) instrument. Gel electrophoresis was carried out according to ref.<sup>1,3</sup>.

#### Preparation of Anhydrides III and IV

A solution of compound I or II (ref.<sup>2,5</sup>) (150  $\mu$ mol) in water (2 ml) was applied on a column (20 ml) of Dowex 50X8 ( $H^+$  form) and eluted with water (Uvicord). The eluate was taken down *in vacuo* and codistilled with dioxane ( $3 \times 5$  ml). The residue was dissolved in dioxane (2.5 ml) and tri-n-butylamine (38  $\mu$ l; 150  $\mu$ mol) was added. After cooling to 10°C, the mixture was treated with isobutyl chloroformate (20  $\mu$ l; 150  $\mu$ mol) and kept at 10°C for 20 min. The solution was made up to 3 ml with dioxane and employed in the condensation reactions.

#### Preparation of Conjugates V and VI

An aliquot amount of the above-prepared solution of the mixed anhydride III or IV (25 and 50  $\mu$ mol, respectively) was added at 10°C to a solution of human serum albumin (69 mg; 1  $\mu$ mol) in 0.1M phosphate buffer, pH 8.0 (4 ml). The mixture was set aside for 1 h at 10°C and then at room temperature overnight. An aliquot (1 ml) was applied on a Sephadex column and eluted under above-mentioned conditions. High-molecular fractions (12–21) were combined, made up to an appropriate volume and used for measurements. Low-molecular UV-absorbing fractions (29–43) were pooled and used for the determination of compounds I and II. Lyophilisation of the high-molecular portion afforded the solid conjugates V and VI (Table II).

#### Preparation of Conjugates VII and VIII

An aliquot of the reagent III or IV (25 or 50  $\mu$ mol, respectively) was added at 10°C to a solution of bovine gamma-globulin (80 mg; 0.5  $\mu$ mol) in 0.01M phosphate buffer, pH 8.0 (4 ml) and the mixture was worked up in the same manner as described for the conjugates V and VI. The results are given in Table II.

#### Determination of Bonded Haptene Content in the Conjugates V–VIII

a) The measurements were performed with the solution of the conjugate (*vide supra*) in an ammonium carbonate buffer, pH 8.7, which was compared with a protein solution of the same concentration at the wavelength of the absorption maximum of the haptene, using extinction coefficients given in Table I.

b) The content of I or II in the eluate from the low-molecular weight fraction (*vide supra*) was determined using the values in Table I. The difference between the starting amount and the amount found in this fraction corresponded to the bound haptene.

#### REFERENCES

1. Camiener G. W., Wechter W. J. in the book: *Progress in Drug Research* (E. Jucker, Ed.), Vol. 16, p. 67. Birkhäuser, Basel 1972.
2. Pischel H., Holý A., Wagner G., Cech D.: *This Journal* 40, 2689 (1975).

3. Ambrosius H.: *Acta Biol. Med. Ger.* 35, 1666 (1976).
4. Wagner G., Nuhn P., Pischel H.: *Wiss. Z. Karl-Marx-Univ. Leipzig, Math.-Naturwiss. R.* 26, 5 (1977); *Chem. Abstr.* 88, 48847a (1978).
5. Holý A., Pischel H.: *This Journal* 42, 2261 (1977).
6. Pischel H., Holý A., Wagner G.: *This Journal* 44, 1634 (1979).
7. Barbanti-Brodano G., Fiume L.: *Experientia* 30, 1180 (1974).
8. Nuhn P., Schilling E., Wagner G.: *J. Prakt. Chem.* 318, 291 (1976).
9. Williams G. A., Chase M. W.: *Methods in Immunology and Immunochemistry*, Vol. I, p. 149. Academic Press, New York and London 1967.
10. Erlanger B. F., Borek G., Beiser S. M., Lieberman S.: *J. Biol. Chem.* 228, 713 (1957).
11. Pischel H., Holý A., Wagner G.: *This Journal* 39, 3773 (1974).
12. Wagner G., Bunk E.: *Pharmazie*, in press.
13. Wagner G., Hanfeld V., Pischel H.: *Pharmazie* 32, 668 (1977).

Translated by M. Tichý.